Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
RNF112-mediated FOXM1 ubiquitination suppresses the proliferation and invasion of gastric cancer
Shengwei Zhang, … , Shiming Yang, Changjiang Hu
Shengwei Zhang, … , Shiming Yang, Changjiang Hu
Published June 8, 2023
Citation Information: JCI Insight. 2023;8(11):e166698. https://doi.org/10.1172/jci.insight.166698.
View: Text | PDF
Research Article Gastroenterology Oncology

RNF112-mediated FOXM1 ubiquitination suppresses the proliferation and invasion of gastric cancer

  • Text
  • PDF
Abstract

Forkhead box M1 (FOXM1) plays a critical role in development physiologically and tumorigenesis pathologically. However, insufficient efforts have been dedicated to exploring the regulation, in particular the degradation of FOXM1. Here, the ON-TARGETplus siRNA library targeting E3 ligases was used to screen potential candidates to repress FOXM1. Of note, mechanism study revealed that RNF112 directly ubiquitinates FOXM1 in gastric cancer, resulting in a decreased FOXM1 transcriptional network and suppressing the proliferation and invasion of gastric cancer. Interestingly, the well-established small-molecule compound RCM-1 significantly enhanced the interaction between RNF112 and FOXM1, which further promoted FOXM1 ubiquitination and subsequently exerted promising anticancer effects in vitro and in vivo. Altogether, we demonstrate that RNF112 suppresses gastric cancer progression by ubiquitinating FOXM1 and highlight the RNF112/FOXM1 axis serves as both prognosis biomarker and therapeutic target in gastric cancer.

Authors

Shengwei Zhang, Jing Wang, Weichao Hu, Lijiao He, Qingyun Tang, Jie Li, Mengmeng Jie, Xinzhe Li, Cheng Liu, Qin Ouyang, Shiming Yang, Changjiang Hu

×

Figure 4

RNF112 physically interacts with and ubiquitinates FOXM1.

Options: View larger image (or click on image) Download as PowerPoint
RNF112 physically interacts with and ubiquitinates FOXM1.
(A) Co-IP anal...
(A) Co-IP analysis of the interaction between RNF112 and FOXM1. HEK293T cells were harvested 48 hours after transfection with FOXM1-FLAG and RNF112-HA, and the cell lysates were used for IP with anti-HA or anti-FLAG agarose beads. Then, HA, FLAG, and FOXM1 were detected by immunoblotting in whole-cell lysates and corresponding precipitates. (B) Immunoblot analysis of whole-cell lysates (WCL) and GST pull-down (PD) products derived from HEK293T cells transfected with RNF112-HA plasmid. (C) Immunofluorescence of RNF112 and FOXM1 in HEK293T cells transfected with RNF112 and FOXM1 expression vectors. Scale bar: 10 μm. (D and E) Schematic graph of truncated RNF112 (D) and FOXM1 protein (E). GBP, guanylate-binding protein family domain; DBD, DNA-binding domain. (F) Co-IP analysis of the interaction between truncated RNF112 and full-length FOXM1 in HEK293T cells. (G) Co-IP analysis of the interaction between truncated FOXM1 mutants and full-length RNF112 in HEK293T cells. (H) Ubiquitination of FOXM1 was tested 48 hours after transfection with RNF112-HA or control in HEK293T cells in the presence of 10 μM MG132 for 8 hours. Complete unedited blots are in the supplemental material.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts